Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
12.87 EUR | -1.88% | +1.22% | +19.73% |
Presenter SpeechNuria Lapeña (Executives)Good day, everyone, and welcome to Grifols Business Update conference cal...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:
- products derived from plasma (77.3%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (14.9%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (5.4%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.3%), European Union (11.7%), the United States and Canada (63.6%) and other (19.4%).
Sector
Pharmaceuticals
Calendar
2024-02-28
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy

Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.12EUR
Average target price
18.48EUR
Spread / Average Target
+40.93%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
+19.73% | 8 589 M $ | |
-10.73% | 81 646 M $ | |
-11.45% | 38 459 M $ | |
-18.84% | 33 151 M $ | |
-23.89% | 25 148 M $ | |
+15.19% | 22 868 M $ | |
-15.03% | 16 689 M $ | |
-7.72% | 14 304 M $ | |
-34.84% | 11 849 M $ | |
+35.82% | 9 398 M $ |
- Stock
- Equities
- Stock Grifols, S.A. - Bolsas y Mercados Espanoles
- News Grifols, S.A.
- Transcript : Grifols, S.A., Q3 2022 Earnings Call, Nov 08, 2022